

InferLink Corporation



El Segundo, California

<https://www.inferlink.com/>

(310) 341-2446

SINCE ITS FOUNDING IN

2011

36 SBIR Awards

15 Employees

SB Socioeconomic Category

1 Awarded Patent (SBIR/STTR)

Scientific Literature



Intervention	Percent	Outcome
atorvastatin arm	Five percent	developed nephropathy

Structured
Output**Solicitation:**

Early Stage Development of Technologies in Biomedical Computing, Informatics, and Big Data Science (R43/R44)

DARPA SBIR Sponsor**NIH PA-14-154 Topic Number****Improved Performance Primary Innovation****Greater Reliability Secondary Innovation**

Automating Scientific Validation Process

Analyzing published scientific research results is time and labor intensive and is often outdated when completed.

InferLink has developed software utilizing artificial intelligence to extract data from published research and validate scientific claims. The software employs deep learning to extract and analyze information from text in scientific articles. The technology has been applied in multiple domains, including extracting the results of clinical trials from biomedical articles and extracting data about machine learning experiments from computer science articles.

IMPACT

Content extraction is an essential enabling technology for open-source intelligence applications. Currently, obtaining data from the scientific literature requires manual effort and thus it is difficult to analyze more than a fraction of the published data. Automating the extraction and analysis of technical information from biomedical and computer science articles will increase the accessibility of a vast store of scientific data.

BEYOND PHASE II

InferLink received a Rapid Innovation Fund award of \$2M from Defense Threat Reduction Agency (DTRA) for automating the aggregation of data about biomaterials from multiple sources. In addition, a spin-off company, Evid Science, was launched during Phase II and this technology is the core of their product offering in the pharmaceutical industry. The company successfully raised \$1M in external VC investments for Evid Science to support business development and Evid Science was recently acquired.